Literature DB >> 8254096

Patients with haemolytic uraemic syndrome caused by Escherichia coli O157: absence of antibodies to Vero cytotoxin 1 (VT1) or VT2.

H Chart1, D Law, B Rowe, D W Acheson.   

Abstract

Serum samples from 30 patients with haemolytic uraemic syndrome (HUS), caused by Escherichia coli O157, and 30 apparently healthy volunteers, were used to examine the immune response of patients to Vero cytotoxins (VT) 1 and VT2. Patients' sera could not be differentiated from control sera using ELISA; and using immunoblotting, none of the sera had antibodies reactive with either the A or B subunits of VT1 or VT2. Examination of sera for antibodies to VT1 and VT2 seems to be of little value in the serodiagnosis of HUS caused by Vero cytotoxin-producing E coli O157.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8254096      PMCID: PMC501695          DOI: 10.1136/jcp.46.11.1053

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies.

Authors:  A Donohue-Rolfe; D W Acheson; A V Kane; G T Keusch
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

Review 2.  Vero cytotoxin-producing strains of Escherichia coli.

Authors:  H R Smith; S M Scotland
Journal:  J Med Microbiol       Date:  1988-06       Impact factor: 2.472

3.  Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.

Authors:  C A Lingwood; H Law; S Richardson; M Petric; J L Brunton; S De Grandis; M Karmali
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

4.  Serum antibodies to Escherichia coli serotype O157:H7 in patients with hemolytic uremic syndrome.

Authors:  H Chart; S M Scotland; B Rowe
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

Review 5.  Hemolytic uremic syndrome.

Authors:  M Levin; M D Walters; T M Barratt
Journal:  Adv Pediatr Infect Dis       Date:  1989
  5 in total
  8 in total

1.  Evidence of persisting serum antibodies to Escherichia coli O157 lipopolysaccharide and Verocytotoxin in members of rural communities in England.

Authors:  J Evans; R M Chalmers; H Chart; R L Salmon; S M Kench; T J Coleman; D Meadows; P Morgan-Capner; P Softley; M Sillis; D R Thomas
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

2.  Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1.

Authors:  D Reymond; M A Karmali; I Clarke; M Winkler; M Petric
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome.

Authors:  K Ludwig; M A Karmali; V Sarkim; C Bobrowski; M Petric; H Karch; D E Müller-Wiefel
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

Review 4.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Immune response to verotoxin 1 and 2 in children with Escherichia coli O157:H7 hemorrhagic colitis and classic hemolytic uremic syndrome.

Authors:  F Proulx; J P Turgeon; G Delage; H Lior; L Lafleur; L Chicoine
Journal:  Can J Infect Dis       Date:  1995-05

Review 6.  Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections.

Authors:  J C Paton; A W Paton
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

7.  Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines.

Authors:  E Konadu; J B Robbins; J Shiloach; D A Bryla; S C Szu
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.609

Review 8.  STxB as an Antigen Delivery Tool for Mucosal Vaccination.

Authors:  Eric Tartour; Ludger Johannes
Journal:  Toxins (Basel)       Date:  2022-03-10       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.